Navik, UmashankerRawat, Pushkar SinghAllawadhi, PrinceKhurana, AmitBanothu, Anil KumarBharani, Kala Kumar2024-01-212024-08-142024-01-212024-08-142022-05-309789811652172978981165216510.1007/978-981-16-5217-2_6http://10.2.3.109/handle/32116/4323Zebrafish is a powerful platform in the modern era of phenotype-based drug discovery and eminent vertebrate model to study disease progression and its pathophysiology. Zebrafish possess several advantages over rodent model including low cost, females that lay up to 300 eggs per week, the optical clarity of embryo, external fertilization, and highly amenable to transgenic modifications using various genetic toolkits. Zebrafish have almost 70% genetic homology with humans, and 82% of disease-causing human proteins are orthologue to zebrafish. The bottleneck in drug discovery is high cost, laborious, and time taking processes to generate hits. Zebrafish provide a novel option to overcome this bottleneck and have enabled rapid drug discovery in the area of cancer, cardiovascular diseases, endocrine diseases, and many more. However, zebrafish cannot completely replace the mammalian model in drug discovery, but it can form a bridge between cell-based assays and mammalian models, thus reducing the overall cost and time in lead generation. Therefore, in this chapter, we have discussed the role of zebrafish as an emerging vertebrate model in the area of endocrinology disorders. � The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2022.en-USDiabetesGonadal hormoneMutantObesityOsteoporosisThyroidTransgenicZebrafishBook chapterhttps://link.springer.com/10.1007/978-981-16-5217-2_6